

May 14, 2015

The Corporate Relations Department  
**BSE LIMITED**  
25<sup>th</sup> Floor, Dalal Street,  
PJ Towers,  
**MUMBAI-400 001**

Dear Sir,

**Sub: Code of Practices and Procedures for Fair Disclosure of Un-Published Price Sensitive Information**


**Ref: Company Code: 524804**

We enclose herewith the Code of Practices and Procedures for Fair Disclosure of Un-Published Price Sensitive Information formulated pursuant to the provisions of Regulation 8 of SEBI (Prohibition of Insider Trading) Regulations, 2015 which has been approved by the Board of Directors of the Company.

Please take the information on record.

Thanking you,

Yours faithfully,  
For AUROBINDO PHARMA LIMITED



A. MOHAN RAMI REDDY  
AVP (Legal) & COMPANY SECRETARY



## AUROBINDO PHARMA LIMITED

### CODE OF PRACTICES AND PROCEDURES FOR FAIR DISCLOSURE OF UNPUBLISHED PRICE SENSITIVE INFORMATION (w.e.f. 15.05.2015)


*(Approved by the Board of Directors of the Company on 29.04.2015)*

[FRAMED UNDER REGULATION 8 (1) OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (PROHIBITION OF INSIDER TRADING) REGULATIONS, 2015]

Aurobindo Pharma Limited (the Company) will adhere to the following so as to ensure timely and adequate disclosure of the Price Sensitive Information with respect to it or its securities which is likely to affect price of the securities.

1. The Company will make prompt public disclosure of unpublished price sensitive information that would impact price discovery no sooner than credible and concrete information comes into being in order to make such information generally available.
2. The Company will make, uniform and universal dissemination of unpublished price sensitive information to avoid selective disclosure.
3. The Compliance Officer of the Company will be the chief investor relations officer to deal with dissemination of information and disclosure of unpublished price sensitive information.
4. The Company will make prompt dissemination of unpublished price sensitive information that gets disclosed selectively, inadvertently or otherwise to make such information generally available.
5. The Company will provide, appropriate and fair response to queries on news reports and requests for verification of market rumors by regulatory authorities.
6. The Company will ensure that, information if any shared with analysts and research personnel is not unpublished price sensitive information.
7. The Company will make transcripts or records of proceedings of meetings with analysts and other investor relations conferences on the website of the Company to ensure official confirmation and documentation of disclosures made.
8. The Company will handle all unpublished price sensitive information on need to know basis.

For AUROBINDO PHARMA LIMITED



A. MOHAN RAMI REDDY  
Associate Vice President (Legal) &  
Company Secretary